With nod from panel, Aerie inches toward FDA approval
Aerie Pharmaceuticals (Nasdaq: AERI) – which is in the process of building out its research and development team locally – is moving closer to U.S. Food and Drug Administration approval.
On Friday, an FDA advisory committee voted in favor of Rhopressa – an Aerie eye drop product candidate for the treatment of glaucoma. The 10-pe rson panel voted unanimously that clinical trials of Rhopressa support its efficacy; it voted 9-1 that its efficacy outweighs safety risks.
While the FDA normally…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Jennifer Henderson Source Type: news
More News: Biotechnology | Clinical Trials | Food and Drug Administration (FDA) | Glaucoma | Health Management